

# Stefânia Forner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1426299/publications.pdf>

Version: 2024-02-01

27  
papers

1,393  
citations

430874

18  
h-index

526287

27  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2099  
citing authors

#	ARTICLE	IF	CITATIONS
1	Generation of a humanized A $\beta$ 2 expressing mouse demonstrating aspects of Alzheimer's disease-like pathology. <i>Nature Communications</i> , 2021, 12, 2421.	12.8	53
2	Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer's disease. <i>Scientific Data</i> , 2021, 8, 270.	5.3	138
3	SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer's Disease. <i>Neurotherapeutics</i> , 2021, 18, 2468-2483.	4.4	5
4	Systematic Phenotyping and Characterization of the 3xTg-AD Mouse Model of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 785276.	2.8	58
5	Model organism development and evaluation for late-onset Alzheimer's disease: MODELAD. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12110.	3.7	63
6	miR-181a negatively modulates synaptic plasticity in hippocampal cultures and its inhibition rescues memory deficits in a mouse model of Alzheimer's disease. <i>Aging Cell</i> , 2020, 19, e13118.	6.7	42
7	Intra- and extracellular $\beta$ -amyloid overexpression via adeno-associated virus-mediated gene transfer impairs memory and synaptic plasticity in the hippocampus. <i>Scientific Reports</i> , 2019, 9, 15936.	3.3	12
8	Amyloid-beta impairs TOM1-mediated IL-1R1 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 21198-21206.	7.1	24
9	Tau underlies synaptic and cognitive deficits for type 1, but not type 2 diabetes mouse models. <i>Aging Cell</i> , 2019, 18, e12919.	6.7	19
10	Astrocytes: From the Physiology to the Disease. <i>Current Alzheimer Research</i> , 2019, 16, 675-698.	1.4	20
11	Past to Future: What Animal Models Have Taught Us About Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S365-S378.	2.6	22
12	Impaired $\alpha$ -AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease. <i>Aging Cell</i> , 2018, 17, e12791.	6.7	58
13	Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony. <i>Trends in Neurosciences</i> , 2017, 40, 347-357.	8.6	327
14	Transplantation of Human Skin-Derived Mesenchymal Stromal Cells Improves Locomotor Recovery After Spinal Cord Injury in Rats. <i>Cellular and Molecular Neurobiology</i> , 2017, 37, 941-947.	3.3	29
15	Delayed decompression exacerbates ischemia-reperfusion injury in cervical compressive myelopathy. <i>JCI Insight</i> , 2017, 2, .	5.0	67
16	Características das pessoas com Acidente Vascular Encefálico atendidas em um centro de referência estadual Characteristics of Encephalic Vascular Accident patients treated at a state reference center. <i>Revista De Pesquisa: Cuidado À Fundamental Online</i> , 2017, 9, 315-320.	0.5	2
17	Inhibition of spinal c-Jun-NH2-terminal kinase (JNK) improves locomotor activity of spinal cord injured rats. <i>Neuroscience Letters</i> , 2016, 621, 54-61.	2.1	9
18	Lipoxin A4 inhibits microglial activation and reduces neuroinflammation and neuropathic pain after spinal cord hemisection. <i>Journal of Neuroinflammation</i> , 2016, 13, 75.	7.2	109

#	ARTICLE	IF	CITATIONS
19	Temporal and Regional Expression of Glucose-Dependent Insulinotropic Peptide and Its Receptor in Spinal Cord Injured Rats. <i>Journal of Neurotrauma</i> , 2016, 33, 261-268.	3.4	3
20	Knowing to care: characterization of individuals with spinal cord injury treated at a rehabilitation center. <i>Fisioterapia Em Movimento</i> , 2015, 28, 77-83.	0.1	3
21	Neuroprotective Effects of Lipoxin A4 in Central Nervous System Pathologies. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	19
22	Neuroprotective effect of the proanthocyanidin-rich fraction in experimental model of spinal cord injury. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 694-704.	2.4	3
23	Antagonism of the transient receptor potential ankyrin 1 (TRPA1) attenuates hyperalgesia and urinary bladder overactivity in cyclophosphamide-induced haemorrhagic cystitis. <i>Chemico-Biological Interactions</i> , 2013, 203, 440-447.	4.0	40
24	Anti-inflammatory lipoxin A <sub>4</sub> is an endogenous allosteric enhancer of CB <sub>1</sub> cannabinoid receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 21134-21139.	7.1	161
25	Effects of kinin B <sub>1</sub> and B <sub>2</sub> receptor antagonists on overactive urinary bladder syndrome induced by spinal cord injury in rats. <i>British Journal of Pharmacology</i> , 2012, 167, 1737-1752.	5.4	19
26	Endothelium dependent expression and underlying mechanisms of des-Arg <sup>9</sup> -bradykinin-induced B1R-mediated vasoconstriction in rat portal vein. <i>Peptides</i> , 2012, 37, 216-224.	2.4	8
27	TRPA1 receptor modulation attenuates bladder overactivity induced by spinal cord injury. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, F1223-F1234.	2.7	78